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Abstract: Clinical manifestations of chronic obstructive pulmonary disease (COPD), including 
airﬂ  ow limitation, dyspnea, and activity limitation, ultimately lead to impaired health-related 
quality of life (HRQoL). This 9-month, randomized, double-blind, multicenter study compared 
the effect of once-daily tiotropium 18 μg and placebo on HRQoL, spirometric parameters, and 
exacerbations in 554 patients with moderate-to-severe COPD. HRQoL was assessed using the 
St. George’s Respiratory Questionnaire (SGRQ) and the new 8-item Visual Simpliﬁ  ed Respira-
tory Questionnaire (VSRQ), which is currently being validated. The primary efﬁ  cacy endpoint 
was the proportion of patients achieving a reduction of at least 4 units in the SGRQ total score 
at study end (Month 9). Mean ± SD baseline SGRQ total score was 47.4 ± 18.1. Signiﬁ  cantly 
more tiotropium-treated patients achieved a reduction of at least 4 units in the SGRQ score 
vs placebo at study end (59.1% vs 48.2%, respectively; p = 0.029). Tiotropium signiﬁ  cantly 
improved spirometric parameters (forced expiratory volume in 1 second [FEV1]: 0.11 ± 0.02 
L vs 0.01 ± 0.02 L; between-group difference: 0.10 ± 0.03 L, p = 0.0001) and reduced exacer-
bations vs placebo. Maintenance treatment with tiotropium provided signiﬁ  cant and clinically 
relevant improvements in HRQoL, as measured by the SGRQ.
Keywords: chronic obstructive pulmonary disease, long-acting anticholinergic, health-related 
quality of life, tiotropium
Introduction
Chronic obstructive pulmonary disease (COPD) is characterized by airﬂ  ow limitation 
that is not fully reversible (Global Initiative for Chronic Obstructive Lung Disease 
2006). Even with the best available care, lung function in patients with COPD pro-
gressively worsens over time. Maintaining or improving health-related quality of life 
(HRQoL) is, therefore, a key treatment goal in COPD and should be one of the main 
parameters for monitoring the disease and assessing the efﬁ  cacy of treatment.
Clinical trials have widely employed health status questionnaires as markers of 
the impact of disease on patients’ health, daily life, and sense of well-being (Spencer 
et al 2001, 2004; Jones et al 2003). Many HRQoL questionnaires exist, including dis-
ease-speciﬁ  c instruments such as the St. George’s Respiratory Questionnaire (SGRQ) 
(Jones et al 1992) and generic instruments such as the 36-item short form (SF-36) 
(McHorney et al 1993). These questionnaires have been used in patients with stable 
COPD and during exacerbations (Spencer et al 2004), as well as in the evaluation of 
new therapies (Spencer et al 2001; Jones et al 2003). In particular, the SGRQ has been 
validated in many languages, including French (Bourbeau et al 2004).
Despite the existence of numerous HRQoL questionnaires, none has been speciﬁ  -
cally designed and validated for use in the treatment of COPD in routine medical 
practice. Indeed, PW Jones recently highlighted the issue that tools used to assess 
HRQoL in clinical trials by pharmaceutical companies and/or payers should be dif-
ferentiated from those designed to detect an improvement in HRQoL in an individual International Journal of COPD 2008:3(2) 302
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patient (Jones 2006). HRQoL is not easy to measure in routine 
medical practice. The lack of a convenient tool in French 
instigated the development of the disease-speciﬁ  c Visual 
Simpliﬁ  ed Respiratory Questionnaire (VSRQ) by Boehringer 
Ingelheim, France. The focus of this paper is on the efﬁ  cacy 
of tiotropium compared with placebo on HRQoL as measured 
by the SGRQ. The VSRQ questionnaire has been included in 
this study to undergo a preliminary evaluation, but the data on 
the validation of this new instrument will not be the subject 
of the current paper and will be published elsewhere.
Tiotropium (Spiriva®; Boehringer Ingelheim GmbH; 
Ingelheim am Rhein, Germany) is a once-daily anticho-
linergic that provides effective 24-hour efﬁ  cacy through 
prolonged M3-receptor blockade and is indicated for main-
tenance treatment of patients with COPD. Previous stud-
ies have consistently shown that tiotropium signiﬁ  cantly 
improves lung function, favorably inﬂ  uences exercise capac-
ity, reduces dyspnea and also the incidence of exacerbations 
in patients with COPD (Casaburi et al 2002; Vincken et al 
2002; Brusasco et al 2003; Celli et al 2003; O’Donnell et al 
2004; Niewoehner et al 2005; Verkindre et al 2005; Dusser 
et al 2006). It has also been shown to improve HRQoL 
compared with placebo (Casaburi et al 2002; Donohue et al 
2002; Vincken et al 2002; Verkindre et al 2005). Further-
more, tiotropium has been shown to be superior to placebo 
in terms of the proportion of patients achieving a reduction 
of at least 4 units in the SGRQ total score (Donohue et al 
2002). However, these studies monitored HRQoL only as a 
secondary efﬁ  cacy parameter.
The primary aim of the present study was to investigate 
the effects of 9 months’ treatment with tiotropium 18 μg on 
HRQoL in patients with moderate-to-severe COPD, using the 
SGRQ. The assessment of HRQoL as a primary endpoint has, 
to our knowledge, not been previously evaluated in any other 
clinical trials of pharmacologic interventions in COPD.
Materials and methods
Patients
Male and female outpatients aged  40 years with a clini-
cal diagnosis of COPD (pre- and post-bronchodilator FEV1 
20%–70% predicted and FEV1/slow vital capacity [SVC] 
 70%,) corresponding to mild, moderate, or severe COPD 
according to 1995 American Thoracic Society criteria 
(American Thoracic Society 1995) and a smoking history 
of  10 pack-years were eligible for inclusion in the study. 
Exclusion criteria were a history of asthma, allergic rhinitis, 
or atopy; regular use of daytime oxygen therapy; a recent 
respiratory tract infection (within the previous 6 weeks); a 
recent history of myocardial infarction (within the previous 
6 months); cardiac arrhythmia requiring drug therapy (within 
the previous year); or hospitalization for either heart failure 
or pulmonary edema (within the previous 3 years).
Study design
This was a 9-month, randomized, double-blind, placebo-
controlled, multicenter, parallel-group study. The trial 
(protocol 205.256) was performed at 123 centers in France. 
Patients were recruited between May 2002 and June 2003, 
and follow up was from August 2002 through April 2004. 
The trial was approved by an ethics committee (Comité 
Consultatif de Protection des Personnes dans la Recherche 
Biomedicale [CCPPRB] of Lille), conducted in accordance 
with the Declaration of Helsinki, and all patients provided 
written informed consent.
Following a screening visit (Day –14), eligible patients 
underwent a 2-week run-in period during which any short-
acting anticholinergics or long-acting β2-agonists were 
washed out. On Day 1 of the study, patients were randomized 
1:1 to receive either tiotropium 18 μg once daily or placebo, 
delivered via the HandiHaler® device (Boehringer Ingelheim 
GmbH; Germany). Patients were assigned using a computer-
generated randomization schedule, with no stratiﬁ  cation 
(block size of 4).
Patients were permitted to use salbutamol (Ventolin®; 
GlaxoSmithKline, UK) delivered via a metered-dose inhaler, 
as needed, for acute symptom relief. Concomitant use of 
theophylline preparations (excluding 24-hour preparations), 
mucolytics, inhaled corticosteroids (ICS), and oral steroids 
(at a dose of  10 mg prednisone daily or equivalent) was 
allowed if the dosage was stabilized for  6 weeks before 
study entry. During the treatment period, patients were not 
allowed to use β-blockers, antileukotrienes, oral or inhaled 
long-acting β2-agonists, short-acting anticholinergics, or any 
other investigational drug. One 10-day course of oral steroids 
was permitted for the treatment of a COPD exacerbation 
during the study period. Investigators were also permitted to 
administer antibiotics as deemed necessary for the treatment 
of exacerbations.
Clinical assessments
Assessments were conducted prior to administration of 
treatment on Day 1 (randomization) and after 3, 6, and 9 
months of treatment. The primary efﬁ  cacy endpoint was 
the proportion of patients achieving a reduction of at least 
4 units in the SGRQ total score at study end (Month 9). In 
order to avoid the introduction of a bias in the completion International Journal of COPD 2008:3(2) 303
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of the HRQoL questionnaires, these were completed prior 
to the spirometric tests using the SGRQ and the VSRQ on 
each test day. The SGRQ consists of a 76-item questionnaire 
split into 3 components: symptoms (assessing distress due 
to respiratory symptoms), activity (assessing the effects of 
breathlessness on mobility and physical activity), and impact 
(assessing the psychosocial impact of disease). The SGRQ 
total score is a composite of the 3 component scores. Scores 
are weighted and range from 0 to 100, with higher scores 
indicating a poorer HRQoL. Currently, a reduction of  4 
units is considered to be the minimal clinically important 
difference by the author of the questionnaire (Jones 2002), 
but this value is currently under debate and subject to review. 
Subgroup analyses were performed according to COPD 
severity, reversibility at baseline, ICS use and occurrence 
of exacerbations during the trial.
The VSRQ consists of 8 items (dyspnea, usual daily 
activities, social activities, quality of sleep, pleasure, energy, 
anxiety, and sexual life) that are each rated from 0 (extreme 
limitation) to 10 (no limitation) on a visual scale. The VSRQ 
total score is the sum of these 8 ratings. An increase indicates 
an improvement in health status. More details about the 
questionnaire and the validation data from this trial will be 
published elsewhere.
FEV1, forced vital capacity (FVC), inspiratory capacity 
(IC), SVC, and forced inspiratory volume in 1 second (FIV1; 
measured at selected sites only) were recorded 30 minutes 
prior to dosing on Day 1 and approximately 24 hours after the 
previous dose of study medication at 3, 6, and 9 months. All 
spirometric tests were conducted in triplicate, and the highest 
measurements were used in subsequent analyses.
Detailed information on exacerbations of COPD was also 
collected. An acute exacerbation was deﬁ  ned as a sustained 
worsening of the patient’s COPD (from the stable state and 
beyond normal day-to-day variation) that was acute in onset 
and necessitated a change in regular medication (Rodriguez-
Roisin 2000). Adverse events were monitored throughout the 
treatment period and coded according to the Medical Diction-
ary for Drug Regulatory Affairs, MedDRA version 7.0.
Statistical analysis
A sample size of 234 patients per treatment group was 
required to provide 80% power to detect a between-group 
difference of 13% in the primary endpoint (proportion of 
patients with  4 units improvement in SGRQ total score). 
This difference corresponds to expected response rates of 
32% and 45% in the placebo and tiotropium groups, respec-
tively (2-sided χ2 test at a 5% conﬁ  dence level). The sample 
size calculation based on a 13% difference was determined 
considering the ﬁ  ndings of the pooled results from two 
6-month trials (Brusasco et al 2003) comparing tiotropium, 
salmeterol and placebo. The difference between tiotropium 
and placebo after 6 months was 10%. The other data taken 
into consideration was the pooled analysis of two 1-year 
placebo-controlled tiotropium trials (Casaburi et al 2002), 
showing a difference of 19% after 12 months.
Due to the fact that this trial had a duration that is in 
between that of the two reference trials and, under the 
assumption that the HRQoL will deteriorate over time, the 
assumption of a 13% difference was taken. Another assump-
tion was that the pattern of concomitant medication use has 
changed over time and that there is a higher likelihood of 
concomitant respiratory medication use in this trial, as com-
pared with the earlier trials used as reference.
Efﬁ  cacy was measured in the full analysis population, 
which included all randomized patients who received 
study medication and had baseline and at least 1 valid post-
treatment measurement. This included patients who dropped 
out prematurely, but these patients were not followed up 
until the projected exit date from the trial. Patients who did 
not adhere to the protocol or who were treated for less than 
30 days were excluded from the per-protocol analyses. The 
safety population included all randomized patients who 
received study medication. Missing individual SGRQ items 
were handled according to the questionnaire authors’ recom-
mendations: missing items from Part 1 or Part 2 (sections 
1 and 7 [last part]) of the questionnaire were imputed as 
negative responses. If individual SGRQ items were missing 
from Part 2 (sections 2–6 and 7 [ﬁ  rst part] of the question-
naire), the total weight was adjusted to take into account the 
missing values. If more than 10 items were missing in these 
sections, then the component score was not included in the 
subsequent analyses. The maximum numbers of missing 
items were 2, 4, and 6 for the symptoms, activity, and impacts 
components, respectively. Moreover, missing SGRQ compo-
nent or total scores were imputed using the last observation 
carried forward method (except if Day 1 was the last visit, in 
which case the patient was excluded). The VSRQ total score 
was calculated from the 8 category scores. As there was no 
speciﬁ  c recommendation for handling missing data, the last 
observation carried forward method was used.
The primary endpoint was analyzed using the Cochran-
Mantel-Haenszel test, stratified by center. Analysis of 
covariance with terms for treatment was used for all the 
HRQoL and spirometric endpoints, with baseline data as 
covariates. Four subgroups were deﬁ  ned: FEV1 severity International Journal of COPD 2008:3(2) 304
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(below and above 50% predicted value) and reversibility at 
baseline, use of concomitant inhaled corticosteroids (yes/no), 
and occurrence of exacerbations (yes/no) during the trial. 
The subgroup analysis of changes from baseline in SGRQ 
total scores was performed using an analysis of covariance 
model with the factors treatment, subgroup, and subgroup-by-
treatment interaction with the baseline values as covariate.
The Fisher exact test was used to compare the frequency 
of exacerbations. The Wilcoxon-Mann-Whitney test was 
used to compare the number of exacerbations days. Exac-
erbation endpoints were calculated per patient per year by 
dividing the number of events by the treatment exposure 
and multiplying by 365.25. Pairwise treatment comparisons 
of time to the ﬁ  rst COPD exacerbation from Kaplan-Meier 
estimates were made using the log rank test.
Results
Patients
A total of 555 patients were randomized and 554 received 
treatment, with 266 receiving tiotropium and 288 receiv-
ing placebo (Figure 1). Patients who dropped out but had 
baseline and post-treatment data were included in the full 
analysis dataset, following the intent-to-treat principle. 492 
patients (tiotropium, n = 247; placebo, n = 245) had suf-
ﬁ  cient data for inclusion in the full analysis population for 
the SGRQ total score analysis. More patients in the placebo 
group discontinued the trial than in the tiotropium group 
(25.7% vs 14.7%, p = 0.0013) (Figure 1). In general, the 2 
treatment groups were well matched at baseline (Table 1). 
However, while the mean ± SD baseline SGRQ total score 
for all patients was 47.4 ± 18.1, the mean SGRQ total 
score was signiﬁ  cantly higher in the placebo group than 
the tiotropium group (difference, 3.2; p = 0.046) (Table 1). 
Furthermore, the mean baseline SGRQ total score was 
signiﬁ  cantly higher in the subgroup of patients with more 
severe disease (FEV1    50% predicted) than in patients 
with milder disease (FEV1   50% predicted) (49.7 vs 43.5, 
respectively).
HRQoL
Compared with the placebo group, signiﬁ  cantly more patients 
in the tiotropium group achieved a reduction of at least 4 
units in the SGRQ total score at Month 9 (Figure 2). At study 
end, 59.1% (146/247) patients in the tiotropium group had 
exceeded this threshold that is, despite ongoing discussions, 
currently regarded as a clinically meaningful improvement 
in SGRQ total score. These patients were considered as 
responders, compared with 48.2% (118/245) of patients in the 
placebo group (difference 10.9% [95% conﬁ  dence interval 
(CI), 2.19% to 19.71%]; p = 0.029).
Tiotropium signiﬁ  cantly improved the SGRQ total score 
on each test day, compared with placebo (all p   0.05) 
(Figure 3a). At study end, adjusted mean (SE) change from 
baseline SGRQ total scores was –8.50 (0.90) for tiotropium 
and –4.32 (0.90) for placebo. The difference between the 2 
Screened (n=664)
Excluded (n=109)
Did not meet inclusion criteria: 67
Consent withdrawn: 9
Adverse events: 11
Lost to follow-up: 3
Other: 19
Randomized to tiotropium (n=266) Randomized to placebo (n=288)
Stopped drug therapy and/or did not complete 
the trial (n=39)
Adverse events: 13
Did not adhere to the protocol: 11
Lost to follow-up: 3
Consent withdrawn: 5
Other: 7 
Completed trial and study drug therapy
(n=227) 
Stopped drug therapy and/or did not complete 
the trial (n=74)
Adverse events: 31
Did not adhere to the protocol: 10
Lost to follow-up: 6
Consent withdrawn: 20
Other: 7
Completed trial and study drug therapy 
(n=214)
Did not receive treatment (n=1)
Figure 1 Trial ﬂ  ow chart.
Table 1 Patient demographics and characteristics at pretreatment 
baseline
 Tiotropium  Placebo
Patients, n  266  288
Sex, M/F  231/35  246/42
Age, years  64.9 ± 9.7  63.5 ± 10.1
Body mass index, kg/m2 26.0  ± 4.8  25.8 ± 4.7
Duration of COPD, years  7.9 ± 7.6  8.0 ± 7.9
Smoking history, pack-years  44.4 ± 21.3  43.0 ± 22.5
Current smokers, n (%)  63 (23.7)  87 (30.2)
HRQoLa  
  SGRQ total score  45.8 ± 17.7  48.9 ± 18.4
  VSRQ total scoreb 47.3  ± 16.0  43.3 ± 16.9
Pulmonary function   
 FEV1, L  1.38 ± 0.44  1.35 ± 0.46
 FEV1, % predicted  47.49 ± 13.27  46.19 ± 12.40
 FVC,  L  2.50  ± 0.68  2.49 ± 0.75
 FEV1/FVC, %  55.30 ± 11.32  54.62 ± 11.27
 IC,  L  2.14  ± 0.69  2.09 ± 0.69
 SVC,  L  2.78  ± 0.74  2.70 ± 0.78
 FIV1, Lc 2.02  ± 0.64  2.04 ± 0.71
Reversibility, n (%)d  108 (40.6)  116 (40.3)
Data are presented as mean ± SD unless otherwise stated.
aLower SGRQ but higher VSRQ scores indicate an improvement.
bVSRQ total score was complete in 415 patients (tiotropium: n = 233;  placebo: n = 237). 
cFIV1 was assessed only at selected sites (80.5% of patients in the full analysis population, 
tiotropium: n = 233; placebo: n = 237).
dReversibility to a short-acting β2-agonist.International Journal of COPD 2008:3(2) 305
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groups exceeded the change of at least 4 units in the SGRQ 
total score currently regarded as meaningful (difference, –4.19 
[95% CI, –6.68 to –1.69]; p = 0.001). Furthermore, compared 
with placebo, tiotropium signiﬁ  cantly improved all 3 SGRQ 
domain scores at study end (all p   0.05) (Figure 3b).
When the overall study population is divided into subgroups 
according to baseline criteria (disease severity and reversibility), 
and on concomitant ICS use and exacerbations during the trial, 
tiotropium showed a consistent efﬁ  cacy pattern across the 
subgroups. The interaction analysis of treatment by subgroup 
did not reveal any signiﬁ  cant interactions (Table 2).
When we compared changes in SGRQ scores in 2 sub-
groups according to FEV1 values (higher or lower than 50% 
predicted), SGRQ total score improvement was statistically 
signiﬁ  cantly better in more severe patients. The difference 
between the tiotropium and the placebo group was, despite the 
consistent effect of tiotropium, small and did not reach statisti-
cal signiﬁ  cance in less severe patients. In patients receiving 
ICS, the difference in SGRQ between tiotropium and placebo 
did not reach statistical signiﬁ  cance, most likely due to the 
low sample size that was not powered to detect a difference. 
When the change in the HRQoL is analyzed by the occurrence 
of exacerbations, patients in the placebo group do show a clear 
relationship between lesser improvement in HRQoL and the 
occurrence of at least one exacerbation. This difference is less 
pronounced in the patients on tiotropium treatment (Table 2).
Spirometry
At study end, tiotropium improved predose FEV1, FIV1, 
FVC, IC, and SVC compared with placebo (all p   0.05) 
(Figure 4). (FIV1 was analyzed in 80.5% of the full analysis 
population.) There was no signiﬁ  cant correlation between 
improvements in the SGRQ total score in both groups 
and changes in FEV1 (r = –0.18), FIV1 (r = –0.14), FVC 
(r = –0.15), IC (r = –0.07), or SVC (r = –0.17) at study 
end. However, when we compared changes from baseline 
in SGRQ scores in 2 subgroups according to FEV1 values 
(higher or lower than 50 % pred), SGRQ total score improve-
ment was statistically signiﬁ  cantly better in the more severe 
patients, in favor of the tiotropium group. In those with 
FEV1  50% pred, the difference between placebo and 
tiotropium in SGRQ improvement from baseline to 9 months 
was –6.00 points (p = 0.0003) (Table 2).
Exacerbations
Patients treated with tiotropium experienced signiﬁ  cantly 
fewer exacerbations per year (1.05 vs 1.83, 43% reduction; 
p = 0.03) and exacerbation days per year (10.5 vs 20.6, 
49% reduction; p = 0.02) than those treated with placebo 
(Table 3). A nonstatistically signiﬁ  cant lower percentage 
of patients experienced 1 or more exacerbations during the 
9-month study in the tiotropium group than in the placebo 
group (38.0% vs 45.1%; p = 0.10). In addition, tiotropium 
signiﬁ  cantly delayed the time to ﬁ  rst exacerbation compared
Figure 2 Percentage of responders (proportion of patients with at least 4 units 
improvement in SGRQ total score during the 9-month study).
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with placebo; mean time to ﬁ  rst exacerbation was 201 days in the 
tiotropium group vs 181 days in the placebo group (p = 0.0081).
Adverse events
The proportion of patients experiencing an adverse event 
was similar in the tiotropium and placebo group (Table 4). 
The incidence of dry mouth was very low and similar in both 
groups (tiotropium, 1.1%; placebo, 0.7%). The proportion 
of patients with drug-related or serious adverse events or 
those withdrawing from the study due to adverse events or 
death were not signiﬁ  cantly different (Table 4). The number 
of deaths occurring during the study (3 in the tiotropium 
group and 6 in the placebo group) was not unexpected, 
given the age, severity of COPD, and prevalence of other 
serious comorbid conditions in the study population. There 
were 3 deaths in the tiotropium group (stroke (1), COPD 
(2)) and 6 deaths in the placebo group (COPD (1), pneu-
monia (1), suicide (2), respiratory failure (1) and aortic 
aneurysm (1)).
Discussion
A fundamental aim of COPD management is to improve 
HRQoL. This 9-month study found that signiﬁ  cantly more 
patients who received maintenance treatment with tiotro-
pium 18 μg daily had a reduction of at least 4 units in the 
SGRQ total score in their HRQoL compared with those who 
received placebo. The clinical signiﬁ  cance of the modiﬁ  ca-
tion of –4 units is a matter of considerable discussion in 
the literature, including that authored by Dr Jones himself. 
However, the value of –4 units will be maintained to facili-
tate the discussion of the results obtained in this study.
These ﬁ  ndings are consistent with previous studies that 
have shown signiﬁ  cant improvements in SGRQ compo-
nent and total scores with tiotropium (Donohue et al 2002; 
Casaburi et al 2002; Vincken et al 2002; Brusasco et al 2003; 
Verkindre et al 2005). The percentage of patients in the 
placebo group who had a reduction of at least 4 units in the 
SGRQ total score in this trial was somewhat higher (48%) 
compared with previous studies (30%–39%) (Casaburi et al 
2002; Brusasco et al 2003; Verkindre et al 2005), although 
Table 2 Mean change from baseline in SGRQ total score at study end according to COPD severity, reversibility at baseline, and ICS 
use during the trial
   Tiotropium    Placebo     
  Number of   Mean (SE) Δ   Number of   Mean (SE) Δ   Difference   95% CI  p value
  patients  from baseline  patients  from baseline  (SE)
COPD severity             
 FEV1  50% predicted  105  –8.85 ± 1.37  93  –7.38 ± 1.44  –1.47 (1.99)  –5.37, 2.44  0.4604
 FEV1  50% predicted  140  –8.18 ± 1.18  150  –2.18 ± 1.14  –6.00 (1.64)  –9.21, –2.78  0.0003
ICS use             
  Not receiving ICS  154  –9.22 ± 1.13  156  –4.81 ± 1.13  –4.41 (1.60)  –7.55, –1.27  0.0061
 Receiving  ICS  93  –7.32  ± 1.46  89  –3.45 ± 1.49  –3.87 (2.09)  –7.97, 0.24  0.0648
Reversibilitya            
 Yes  101  –8.78  ± 1.40  100  –4.20 ± 1.41  –4.58 (1.99)  –8.49, –0.68  0.0215
 No  143  –8.25  ± 1.18  144  –4.48 ± 1.17  –3.76 (1.66)  –7.02, –0.50  0.0239
Exacerbation            
 Yes  95  –7.21  ± 1.44  119  –2.15 ± 1.28  –5.06 ± 1.92  –8.84, –1.28  0.0089
 No  152  –9.33  ± 1.14  126  –6.35 ± 1.25  –2.98 ± 1.69  –6.30, 0.35  0.0791
Lower SGRQ total scores indicate an improvement.
Means are adjusted for baseline SGRQ total scores using the following analysis of covariance model: Change from baseline of SGRQ total score = treatment + subgroup + sub-
group-by-treatment interaction + baseline.
aReversibility to a short-acting β2-agonist.
Full analysis set was analyzed. Number of patients with available data may differ in each subgroup.
The interaction of treatment and subgroup was not signiﬁ  cant with p values of 0.0787, 0.8364, 0.7510, and 0.4177, respectively for severity of the illness, ICS use, reversibility, 
and exacerbation on treatment.
Figure 4   Adjusted mean (SE) change from baseline in spirometric parameters at 
study end (means adjusted for baseline values).
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the proportions are similar to those reported by Donohue et al 
(tiotropium: 51%; placebo: 42%) (Donohue et al 2002). While 
more placebo-treated patients withdrew from the study than 
those receiving tiotropium, this does not entirely explain the 
high placebo response as missing scores were imputed. The 
present study was performed over a 2-year period, with 
about 50% of patients identiﬁ  ed and recruited in the ﬁ  rst 
year; however, there was no change in COPD management 
during the 2 years. Therefore, there is no clear explanation 
for the higher-than-expected proportion of placebo-treated 
patients with HRQoL improvements. These levels for placebo 
responders are consistent with data from 4 internal studies of 
tiotropium, where the rate of placebo response was 29%–42% 
(data on ﬁ  le, Boehringer Ingelheim).
Nevertheless, the higher-than-expected percentage of 
responders in the placebo group is possibly explained by 
the focus of both patients and physicians on monitoring 
HRQoL as the primary endpoint of the trial. Furthermore, 
both may be supposed to have had higher expectations of 
the effect of tiotropium as the study was conducted at a time 
when tiotropium was already available in other European 
countries, but not in France: this assumption, nevertheless, 
remains hypothetical.
The mean SGRQ total score was signiﬁ  cantly lower in the 
tiotropium group compared with the placebo group at base-
line; however, all results presented are baseline adjusted.
Two previous 1-year studies have assessed the effects of 
tiotropium on HRQoL compared with placebo or ipratropium 
(Casaburi et al 2002; Vincken et al 2002). In both these trials, 
improvement in SGRQ total scores reached a plateau after 3 
to 6 months of treatment. Based on these data, 9 months was 
chosen as an appropriate timeframe for this study. However, 
future studies should address whether the observed improve-
ments in HRQoL with tiotropium treatment are sustained 
over the longer term (Decramer et al 2004). Furthermore, 
future studies should compare the effects of tiotropium vs 
short-acting anticholinergics or long-acting β2-agonists on 
HRQoL as a primary outcome.
We have conducted a number of subanalyses in this trial 
and tiotropium has consistently been shown to improve 
patients’ HRQoL. As expected, the mean baseline SGRQ 
total score was signiﬁ  cantly higher in patients with more 
severe disease (FEV1   50% predicted) than in those with 
milder disease (FEV1   50% predicted). In the subgroup 
analyses, tiotropium signiﬁ  cantly improved SGRQ total 
score vs placebo in patients with more severe COPD 
(FEV1   50% predicted). In the patients with milder COPD 
and an FEV1   50% predicted, this difference did not reach 
statistical signiﬁ  cance, despite the consistent efﬁ  cacy of 
tiotropium. This ﬁ  nding is due to an unexpectedly high 
response in the placebo group in this subanalysis. Why this 
high response occurred cannot be explained from the data, 
due to the small subgroups analyzed here and the resulting 
lack of power, the possibility of a chance ﬁ  nding cannot 
be excluded. Another potential explanation could be that 
the differences in the drop-out rates between tiotropium 
and placebo might have contributed to this ﬁ  nding, but this 
remains speculative.
Compared with placebo, tiotropium also provided sig-
niﬁ  cantly greater improvements in SGRQ total score in 
patients not receiving ICS during the trial. In the subgroup of 
patients receiving ICS, there was a trend towards a signiﬁ  cant 
improvement vs placebo and a statistically signiﬁ  cant change 
vs baseline.
HRQoL has been recognized as a key outcome mea-
sure in COPD as it has been associated with lung function 
decline, exercise performance, and healthcare utilization 
Table 4 Adverse event proﬁ  le
 Tiotropium  Placebo
Patients, n  266  288
At least 1 adverse event  162 (60.9)  193 (67.0)
Drug-related adverse events  12 (4.5)  8 (2.8)
Deaths  3 (1.1)  6 (2.1)
Serious adverse events  42 (15.8)  38 (13.2)
Adverse events leading   5 (1.9)  16 (5.6)
to discontinuation
Selected adverse events:a  
  COPD exacerbations  65 (24.4)  80 (27.8)
  Bronchitis  27 (10.2)  33 (11.5)
  Superinfection of the lung  18 (6.8)  20 (6.9)
  Rhinitis  9 (3.4)  7 (2.4)
Data expressed as n (%) unless otherwise indicated.
aOccurring in 3% or more of patients by treatment.
Table 3 Percentage of patients with  1 exacerbation, and mean number of exacerbations and exacerbation days per patient per 
year
  Tiotropium  Placebo  Difference  95% CI  p value
Patients with  1 exacerbation, %  38.0  45.1  –7.2  –15.4, 1.00  0.1013
Number of exacerbations/patient/year, n  1.05  1.83  –0.77  –1.37, –0.20  0.0287
Number of exacerbation days/patient/year, days  10.5  20.6  –10.1  –16.5, –3.64  0.0213International Journal of COPD 2008:3(2) 308
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(Decramer et al 2005). Although the SGRQ has been proved 
unequivocally to be a useful tool to measure HRQoL in clini-
cal trials, this large 76-item questionnaire is difﬁ  cult to use 
for assessing individual patients in daily medical practice. 
Another recently developed instrument, the self-administered 
chronic respiratory questionnaire (CRQ), may be useful in 
clinical practice but had not been validated in French at the 
time of the study (Schunemann et al 2005). For this reason, 
the shorter 8-item VSRQ (French language version) has been 
developed and included in the present study. The VSRQ has 
the advantages of being both easy to use and unidimensional. 
However, further studies are needed to conﬁ  rm its clinical 
responsiveness in individual patients.
In agreement with observations from previous large-
scale clinical studies (Casaburi et al 2002; Vincken et al 
2002; Brusasco et al 2003; Celli et al 2003), tiotropium 
signiﬁ  cantly improved spirometric parameters vs placebo. 
The physiologic hallmark of COPD is expiratory ﬂ  ow 
limitation (O’Donnell et al 1998, 1999). In this study, 
treatment with tiotropium led to signiﬁ  cant improvements 
in FEV1, FIV1, FVC, IC, and SVC compared with placebo. 
We hypothesize that the observed improvement in airﬂ  ow 
and reduction in hyperinﬂ  ation (measured by FVC, IC, and 
SVC) with tiotropium plays a major role in dyspnea relief, 
which allows patients to increase their day-to-day activ-
ity, thereby improving their HRQoL. Increasing evidence 
suggests that FEV1 is only weakly correlated with patient-
centered outcomes, with consistently low correlation 
between lung function and SGRQ total scores (O’Donnell 
et al 1998, 1999). In agreement with these ﬁ  ndings, we did 
not ﬁ  nd a relevant correlation between improvements in 
FEV1 and SGRQ total score at study end. In addition, this 
was the ﬁ  rst study to investigate the impact of tiotropium 
on FIV1. Improvements in FIV1 after salbutamol inhalation 
have been shown to be closely correlated with dyspnea 
relief at rest (Taube et al 2000). Tiotropium signiﬁ  cantly 
improved this lung function parameter to a similar extent 
as FEV1, FVC, IC, and SVC.
Tiotropium also signiﬁ  cantly reduced the frequency of 
exacerbations and the number of exacerbation days over the 
9-month treatment period. Since exacerbations have been 
shown to adversely affect patients’ health status (Kessler 
et al 2006; Celli et al 2007), a reduction in their frequency, 
the number of exacerbation days, or the time to ﬁ  rst exacer-
bation, for example, would be highly likely to be associated 
with an improvement in patients’ HRQoL.
In summary, compared with placebo, maintenance treat-
ment with tiotropium 18 μg daily for 9 months provides 
statistically and clinically significant improvements in 
HRQoL in patients with COPD, assessed using the SGRQ. 
These results cannot be extrapolated to patients who require 
daytime oxygen therapy or have a signiﬁ  cant disease other 
than COPD. In addition, tiotropium signiﬁ  cantly improved 
spirometric parameters and reduced the incidence of exac-
erbations and the number of exacerbation days in patients 
with COPD.
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